Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 8 of 18
Next
>>
>
176 to 200 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	AS605240	2	72	sigmoid	sigmoid	BT20 AS-605240 0 2 72	8	1.846	4509270.0	0.729	0.203	320.0	0.31	0.101	0.845	0.00373	NA	4.4e+12	0.764	0.821	56.5	0.46	0.101	0.843	0.00388	NA
HCC70	PI103	2	72	sigmoid	sigmoid	HCC70 PI-103 0 2 72	8	1.739	1.19	0.0238	0.151	2.67	-0.766	1.15	0.997	2.59e-08	NA	1.68	0.312	0.885	1.68	0.0	1.21	0.996	6.86e-08	NA
HCC70	PIK-93	2	72	sigmoid	sigmoid	HCC70 PIK-93 0 2 72	8	1.705	4.34	0.647	0.0132	9.3	-1.0	1.44	0.888	0.0014	NA	6.01	0.718	0.991	6.01	0.0	1.49	0.872	0.00208	NA
HCC70	WYE-125132	2	72	sigmoid	sigmoid	HCC70 WYE-132 0 2 72	8	1.675	0.213	0.471	0.332	0.0211	0.467	1.18	0.996	6.89e-08	NA	Inf	0.598	0.744	0.0194	0.595	1.17	0.996	7.52e-08	NA
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
HCC38	PI103	2	72	sigmoid	sigmoid	HCC38 PI-103 0 2 72	8	2.094	0.856	0.226	0.167	0.672	0.135	1.3	0.986	2.7e-06	NA	1.04	0.359	0.851	0.488	0.33	1.43	0.981	6.52e-06	NA
BT-549	CAL-101	2	72	sigmoid	sigmoid	BT549 idelalisib 0 2 72	8	1.975	Inf	0.792	0.0561	4.65	0.526	0.693	0.933	0.000307	NA	43.0	0.805	0.946	43.0	0.0	0.548	0.932	0.000314	NA
BT-549	Alpelisib	2	72	sigmoid	sigmoid	BT549 alpelisib 0 2 72	8	1.927	Inf	0.832	0.0409	4.24	0.663	0.548	0.706	0.0254	NA	Inf	0.844	0.962	4.26	0.686	0.542	0.696	0.0282	NA
BT-20	PIK-93	2	72	sigmoid	sigmoid	BT20 PIK-93 0 2 72	8	1.798	0.792	0.155	0.286	14.1	-1.0	0.382	0.81	0.00687	NA	2.8	0.373	0.764	2.8	0.0	0.344	0.77	0.0121	NA
HCC38	MK2206	2	72	sigmoid	sigmoid	HCC38 MK-2206 0 2 72	8	2.159	Inf	0.788	0.0476	0.776	0.775	1.99	0.972	2.1e-05	NA	Inf	0.785	0.951	0.752	0.772	1.98	0.969	2.9e-05	NA
HCC70	Omipalisib	2	72	sigmoid	sigmoid	HCC70 omipalisib 0 2 72	8	1.682	0.00746	-0.705	1.01	0.0241	-0.703	0.749	0.991	6.69e-07	NA	0.0135	0.0399	0.359	0.0121	0.0458	0.852	0.989	1.45e-06	NA
HCC70	KIN001-244	2	72	flat	flat	HCC70 KIN001-244 0 2 72	8	1.684	Inf	0.898	-0.0201	0.0	0.898	0.01	0.508	0.119	1.01	Inf	0.916	1.02	0.0	0.916	0.01	-0.0458	1.0	1.01
HCC38	KIN001-244	2	72	flat	flat	HCC38 KIN001-244 0 2 72	8	2.210	Inf	0.948	0.0304	0.0	0.948	0.01	-0.0213	1.0	0.969	Inf	0.944	0.967	0.0	0.944	0.01	-0.0218	1.0	0.966
BT-20	PI103	2	72	sigmoid	sigmoid	BT20 PI-103 0 2 72	8	1.725	0.235	-0.21	0.388	0.289	-0.212	1.7	0.975	1.64e-05	NA	0.319	0.202	0.721	0.239	0.205	1.81	0.961	5.88e-05	NA
BT-20	CAL-101	2	72	flat	flat	BT20 idelalisib 0 2 72	8	1.768	Inf	0.818	0.0943	0.0	0.818	0.01	0.226	0.463	0.898	Inf	0.845	0.918	0.0	0.845	0.01	0.222	0.471	0.912
HCC70	GDC-0980	2	72	sigmoid	sigmoid	HCC70 apitolisib 0 2 72	8	1.676	0.318	-0.0849	0.284	0.451	-0.205	0.983	0.976	1.34e-05	NA	0.536	0.27	0.795	0.285	0.252	1.11	0.972	2.28e-05	NA
HCC38	Omipalisib	2	72	sigmoid	sigmoid	HCC38 omipalisib 0 2 72	8	2.124	0.0404	-0.47	0.634	0.45	-1.0	0.456	0.979	9.71e-06	NA	0.0507	0.0595	0.494	0.0507	0.0	0.556	0.96	6.44e-05	NA
HCC38	GDC-0980	2	72	sigmoid	sigmoid	HCC38 apitolisib 0 2 72	8	2.159	0.33	0.153	0.279	0.253	0.117	1.0	0.992	4.91e-07	NA	0.385	0.304	0.749	0.165	0.308	1.13	0.994	2.09e-07	NA
BT-549	BX-912	2	72	sigmoid	sigmoid	BT549 BX-912 0 2 72	8	1.948	1.04	0.33	0.126	0.84	0.329	5.0	0.99	1.01e-06	NA	1.28	0.452	0.892	0.808	0.451	5.0	0.987	2.4e-06	NA
HCC70	Pictilisib	2	72	sigmoid	sigmoid	HCC70 pictilisib 0 2 72	8	1.783	0.811	0.124	0.189	0.858	-0.0372	1.27	0.973	2.08e-05	NA	1.25	0.358	0.852	0.678	0.278	1.32	0.963	5.09e-05	NA
BT-549	Buparlisib	2	72	sigmoid	sigmoid	BT549 buparlisib 0 2 72	8	1.913	0.681	-0.306	0.217	1.08	-0.538	1.59	0.998	1.31e-08	NA	0.821	0.132	0.838	0.769	0.0514	1.66	0.996	8.95e-08	NA
HCC70	CAL-101	2	72	sigmoid	sigmoid	HCC70 idelalisib 0 2 72	8	1.738	Inf	0.62	0.0432	0.959	0.611	3.13	0.965	4.31e-05	NA	Inf	0.693	0.965	0.935	0.686	3.13	0.96	6.52e-05	NA
HCC38	Pictilisib	2	72	sigmoid	sigmoid	HCC38 pictilisib 0 2 72	8	2.112	Inf	0.622	0.0838	0.644	0.58	1.32	0.933	0.000298	NA	Inf	0.642	0.918	0.568	0.612	1.36	0.922	0.000475	NA
HCC38	Everolimus	2	72	sigmoid	flat	HCC38 everolimus 0 2 72	8	2.170	8323.0	0.58	0.376	0.000127	0.417	0.1	0.688	0.0303	NA	Inf	0.6	0.637	0.0	0.6	0.01	0.509	0.119	0.637
HCC70	Alpelisib	2	72	flat	flat	HCC70 alpelisib 0 2 72	8	1.799	Inf	0.748	0.0777	0.0	0.748	0.01	0.00864	0.974	0.907	Inf	0.785	0.932	0.0	0.785	0.01	0.00534	0.984	0.919

|<
<<
Previous
Page 8 of 18
Next
>>
>
176 to 200 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)